Categories
Change Password!
Reset Password!
A 10-year retrospective cohort study was carried out to systematically explore the risk of developing non-melanoma skin cancer (NMSC) following ruxolitinib exposure in polycythemia or myelofibrosis patients.
People with polycythemia vera or myelofibrosis taking ruxolitinib should
be regularly monitored for skin cancer.
A 10-year
retrospective cohort study was carried out to systematically explore the risk
of developing non-melanoma skin cancer (NMSC) following ruxolitinib exposure in
polycythemia or myelofibrosis patients.
A
ten-year retrospective cohort of polycythemia or myelofibrosis people were
identified and matched on age, race, gender, disease diagnosis, Charlson
comorbidity index, and follow-up time. The hazard ratio (HR) for NMSC
(comprised of squamous cell carcinoma and basal cell carcinoma) after
ruxolitinib exposure, adjusted for covariates was the major endpoint.
The study
incorporated 564 participants (188 participants exposed to ruxolitinib for at
least four weeks while 376 participants were unexposed). Ruxolitinib-exposed
polycythemia or myelofibrosis people had an adjusted NMSC HR of 2.69.
Particularly, ruxolitinib use was more strongly linked with squamous cell
carcinoma, HR=3.24. The non-Janus kinase-2 gene [JAK2] mutated people exhibited
an even greater risk of squamous cell carcinoma, HR=7.40.
The
real-world results demonstrated that the risk of squamous cell carcinoma is
elevated in polycythemia or myelofibrosis people taking ruxolitinib and
supports consideration of skin cancer monitoring.
The Journal of the American Academy of Dermatology
A 10-year retrospective cohort study of ruxolitinib and association with non-melanoma skin cancer in polycythemia vera and myelofibrosis patients
John Q Lin et al.
Comments (0)